Walgreens Boots Alliance, Inc. vs Madrigal Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: Walgreens vs. Madrigal

__timestampMadrigal Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 20141574600017992000000
Thursday, January 1, 20151339200022400000000
Friday, January 1, 2016929000023910000000
Sunday, January 1, 2017767200023813000000
Monday, January 1, 20181529300024694000000
Tuesday, January 1, 20192264800023557000000
Wednesday, January 1, 20202186400025436000000
Friday, January 1, 20213731800024586000000
Saturday, January 1, 20224813000027295000000
Sunday, January 1, 202310814600034205000000
Monday, January 1, 202428113000000
Loading chart...

In pursuit of knowledge

SG&A Expense Trends: Walgreens Boots Alliance vs. Madrigal Pharmaceuticals

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding the financial dynamics of key players is crucial. Over the past decade, Walgreens Boots Alliance, Inc. and Madrigal Pharmaceuticals, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses.

A Decade of Financial Insights

From 2014 to 2023, Walgreens Boots Alliance consistently reported SG&A expenses in the range of $17.7 billion to $28.1 billion, reflecting a steady growth of approximately 43%. In contrast, Madrigal Pharmaceuticals, a smaller entity, exhibited a more volatile pattern, with expenses surging by over 600% from 2014 to 2023. This dramatic increase highlights Madrigal's aggressive expansion and investment strategies.

Missing Data and Future Projections

While 2024 data for Madrigal is unavailable, Walgreens continues its upward trajectory, projecting further growth. These insights offer a glimpse into the strategic priorities and operational efficiencies of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025